IMM2510, a differentiated PD-L1xVEGF bispecific antibody with upcoming data in H2 2025. Click to read why TIL is a Hold.

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration ...

BNT327 was originally developed by China-based Biotheus; BioNTech completed its $800 million acquisition of the biotech in February, gaining full control of the bispecific antibody.

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...